Cochrane · systematic review · CD001928
Calcium antagonists for acute ischemic stroke
Zhang, J, Liu, J, Li, D, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
StrokeAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
35
current version
GRADE rated
26
No studies
9
Included studies
NR
No studies 9 · 25.7%Ungraded 0 · 0%Very low 0 · 0%Low 14 · 40%Moderate 12 · 34.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Calcium antagonists versus placebo for acute ischemic stroke
Population: people with acute ischemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death or dependency at end of Calcium antagonists vs placebo | RR 1.05 [0.98, 1.13] | 22 studies · 6684 participants | Moderate Downgraded: risk of bias |
Death at the end of treatment Calcium antagonists vs placebo | RR 1.06 [0.93, 1.2] | 22 studies · 6323 participants | Moderate Downgraded: risk of bias |
Death at the end of Calcium antagonists vs placebo | RR 1.07 [0.98, 1.17] | 31 studies · 7483 participants | Moderate Downgraded: risk of bias |
Recurrence of stroke at the end of Calcium antagonists vs placebo | RR 0.93 [0.56, 1.54] | 9 studies · 2460 participants | Moderate Downgraded: risk of bias |
Adverse events during treatment period Calcium antagonists vs placebo | RR 1.18 [0.81, 1.74] | 13 studies · 5095 participants | Moderate Downgraded: risk of bias |
Hypotension during treatment period Calcium antagonists vs placebo | RR 1.43 [0.61, 3.38] | 6 studies · 1667 participants | Moderate Downgraded: risk of bias |
Mean systolic blood pressure during or at end of treatment Calcium antagonists vs placebo | no estimate extracted | 3 studies · 630 participants | Low Downgraded: risk of bias, imprecision |
Nimodipine versus placebo for acute ischemic stroke
Population: people with acute ischemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death or dependency at end of Nimodipine vs placebo | RR 1.06 [0.97, 1.14] | 19 studies · 6093 participants | Moderate Downgraded: risk of bias |
Death at the end of treatment Nimodipine vs placebo | RR 1.02 [0.88, 1.19] | 16 studies · 5163 participants | Moderate Downgraded: risk of bias |
Death at the end of Nimodipine vs placebo | RR 1.05 [0.96, 1.16] | 24 studies · 6312 participants | Moderate Downgraded: risk of bias |
Recurrence of stroke at the end of Nimodipine vs placebo | RR 0.98 [0.96, 1.11] | 6 studies · 1677 participants | Moderate Downgraded: risk of bias |
Adverse events during treatment period Nimodipine vs placebo | RR 0.93 [0.74, 1.16] | 11 studies · 4604 participants | Moderate Downgraded: risk of bias |
Hypotension during treatment period Nimodipine vs placebo | RR 1.26 [0.5, 3.14] | 5 studies · 1648 participants | Moderate Downgraded: risk of bias |
Mean systolic blood pressure during or at end of treatment Nimodipine vs placebo | no estimate extracted | 3 studies · 630 participants | Low Downgraded: risk of bias, imprecision |
Flunarizine versus placebo for acute ischemic stroke
Population: people with acute ischemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death or dependency at end of Flunarizine vs placebo | RR 0.81 [0.34, 1.94] | 2 studies · 357 participants | Low Downgraded: risk of bias, imprecision |
Death at the end of treatment Flunarizine vs placebo | RR 1.31 [0.94, 1.82] | 3 studies · 790 participants | Low Downgraded: risk of bias, imprecision |
Death at the end of Flunarizine vs placebo | RR 1.34 [1.01, 1.77] | 3 studies · 790 participants | Low Downgraded: risk of bias, imprecision |
Recurrence of stroke at the end of Flunarizine vs placebo | RR 0.82 [0.35, 1.97] | 2 studies · 764 participants | Low Downgraded: risk of bias, imprecision |
Adverse events during treatment period Flunarizine vs placebo | RR 3.16 [1.91, 5.21] | 1 study · 331 participants | Low Downgraded: risk of bias, imprecision |
Hypotension during treatment period Flunarizine vs placebo | no estimate extracted | NR | No studies |
Mean systolic blood pressure during or at end of treatment Flunarizine vs placebo | no estimate extracted | NR | No studies |
Isradipine versus placebo for acute ischemic stroke
Population: people with acute ischemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death or dependency at end of Isradipine vs placebo | RR 1.01 [0.74, 1.4] | 1 study · 234 participants | Low Downgraded: risk of bias, imprecision |
Death at the end of treatment Isradipine vs placebo | no estimate extracted | NR | No studies |
Death at the end of Isradipine vs placebo | RR 1.05 [0.6, 1.85] | 1 study · 234 participants | Low Downgraded: risk of bias, imprecision |
Recurrence of stroke at the end of Isradipine vs placebo | no estimate extracted | NR | No studies |
Adverse events during treatment period Isradipine vs placebo | no estimate extracted | NR | No studies |
Hypotension during treatment period Isradipine vs placebo | no estimate extracted | NR | No studies |
Mean systolic blood pressure during or at end of treatment Isradipine vs placebo | no estimate extracted | NR | No studies |
Other calcium antagonists versus placebo for acute ischemic stroke
Population: people with acute ischemic stroke
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death or dependency at end of Other calcium antagonists vs placebo | no estimate extracted | NR | No studies |
Death at the end of treatment Other calcium antagonists vs placebo | RR 0.98 [0.58, 1.66] | 3 studies · 370 participants | Low Downgraded: risk of bias, imprecision |
Death at the end of Other calcium antagonists vs placebo | RR 0.84 [0.45, 1.56] | 3 studies · 147 participants | Low Downgraded: risk of bias, imprecision |
Recurrence of stroke at the end of Other calcium antagonists vs placebo | no estimate extracted | 1 study · 19 participants | Low Downgraded: risk of bias, imprecision |
Adverse events during treatment period Other calcium antagonists vs placebo | RR 1.19 [0.52, 2.72] | 1 study · 160 participants | Low Downgraded: risk of bias, imprecision |
Hypotension during treatment period Other calcium antagonists vs placebo | RR 5.5 [0.3, 101.28] | 1 study · 19 participants | Low Downgraded: risk of bias, imprecision |
Mean systolic blood pressure during or at end of treatment Other calcium antagonists vs placebo | no estimate extracted | NR | No studies |